Stay updated with breaking news from Hermann Einsele. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
CARVYKTI is Legend Biotech's first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR)
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace
CARVYKTI® is Legend Biotech's first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demo